Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Key Terms

ophthalmic medical

Relating to the eye and its care, including medicines, drops, diagnostic tools and surgical devices used to prevent, diagnose or treat eye conditions. Investors care because ophthalmic products form a distinct market with specialized safety approvals, manufacturing needs and payer coverage, so success or failure in this area can drive steady revenue or costly setbacks—think of it as a niche, high‑safety consumer product line for vision health.

glaucoma medical

Glaucoma is a group of eye diseases that slowly damage the optic nerve, often because fluid buildup raises pressure inside the eye, and can lead to permanent vision loss if untreated. For investors, glaucoma matters because it creates sustained demand for medications, surgical devices, diagnostics and follow-up care; breakthroughs or approvals can drive sales and market value much like fixing a clogged drain prevents damage to a house’s wiring.

corneal disorders medical

Corneal disorders are medical conditions that damage the cornea, the clear front surface of the eye, causing symptoms like pain, blurred vision, scarring or increased infection risk. They matter to investors because diagnosing and treating these conditions supports markets for drugs, surgical devices, implants and diagnostic tools; advances, approvals or safety setbacks can change a company’s revenue outlook the way a common mechanical fault creates steady demand for repairs and replacements.

retinal diseases medical

Retinal diseases are conditions that damage the retina, the light-sensitive layer at the back of the eye that works like a camera sensor to convert images into signals the brain can read. Investors care because these conditions drive demand for drugs, surgical devices, and diagnostic tests; breakthroughs, approvals, or setbacks can change a company’s future sales prospects, regulatory risk and patient access, much like a new technology reshaping a market.

webcast technical

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.

A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose^® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251216607694/en/

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation